Chronic Treatment With N -acetylcysteine Improves Cardiac Function but Does Not Prevent Progression of Cardiomyopathy in Syrian Cardiomyopathic Hamsters

Abstract

Oxidative stress has been postulated to contribute to the onset and development of heart failure (HF). The efficacy of antioxidant therapy in HF, however, remains controversial. This study evaluates the effect of the antioxidant N-acetylcysteine (NAC, 1 g/kg per day) on cardiovascular function in 2- and 6-month-old Bio-TO2 Syrian cardiomyopathic hamsters (SCH) after treatment for 1 month and 5 months with this drug. Endothelial function, systolic blood pressure (SBP), and echocardiographic parameters were evaluated. Age-matched F1-B golden hamsters were used as controls. One month of NAC administration significantly decreased SBP in 2-month-old SCH (n = 5, P < 0.001) without modifying echocardiographic values. Five-month treatment of cardiomyopathic animals with the antioxidant improved the acetylcholine-induced relaxation in aortic rings by 24% (E_Max value from 45.8% ± 4% to 55.3% ± 2% n = 7, P < .05) but did not modify EC₅₀ values for the acetylcholine concentration-response curve. In addition, 5-month administration of NAC to SCH increased ejection fraction from 39% ± 4% to 57% ± 4% (n = 11, P < .001) and decreased left ventricular end-diastolic and end-systolic volumes (from 0.38 ± 0.04 mL/100 g body weight (BW) and 0.22 ± 0.03 mL/100 g BW, before, to 0.24 ± 0.04 mL/100 g BW and 0.12 ± 0.03 mL/100 g BW after treatment, P < .01). Cardiac output index also improved after 5 months of treatment, although it did not reach statistical significance. These results suggest that antioxidant therapy alone decreases ventricular dilatation and improves cardiovascular function in this animal model of dilated cardiomyopathy, but it does not prevent the appearance of HF.

Keywords

N-acetylcysteine heart failure Syrian cardiomyopathic hamsters oxidative stress

References

Roger VL , Weston SA , Redfield MM , et al. Trends in heart failure incidence and survival in a community-based population. JAMA. 2004;292(3):344-350.

Boudina S. , Abel ED Diabetic cardiomyopathy revisited. Circulation. 2007;115(25):3213-3223.

Escobales N. , Ramos JA , Santacana G. , Crespo MJ. Hemodynamic alterations in the coronary circulation of cardiomyopathic hamsters: age and Ang II-dependent mechanisms. J Card Fail. 2009;15(10):929-938.

Pacher P. , Beckman JS , Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev. 2007;87(1):315-424.

Williams IA , Allen DG The role of reactive oxygen species in the hearts of dystrophin-deficient mdx mice. Am J Physiol Heart Circ Physiol. 2007;293(3):H1969-H1977.

Münzel T. , Sinning C. , Post F. , Warnholtz A. , Schulz E. Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction. Ann Med. 2008;40(3):180-196.

Andrews NP , Prasad A. , Quyyumi AA N-acetylcysteine improves coronary and peripheral vascular function. J Am Coll Cardiol. 2001;37(1):117-123.

Suter PM , Domenighetti G. , Schaller MD , Laverrière MC , Ritz R. , Perret C. N-acetylcysteine enhances recovery from acute lung injury in man. A randomized, double-blind, placebo-controlled clinical study. Chest. 1994;105(1):190-194.

Rowbotham DS , Wendon JA , Harrison PM N-acetylcysteine infusion in viral myocarditis: a case report. Int J Cardiol. 1997; 60(3):315-316.

10.

Aruoma OI , Halliwell B. , Hoey BM , Butler J. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med. 1989;6(6):593-597.

11.

Crespo MJ , Escobales N. , Altieri PI Altered vascular function in early stages of heart failure in hamsters. J Card Fail. 1997;3(4): 311-318.

12.

Crespo MJ Vascular alterations during the development and progression of experimental heart failure. J Card Fail. 1999;5(1): 55-63.

13.

Crespo MJ Interaction between AT-1 and alpha-1 adrenergic receptors in cardiomyopathic hamsters. J Card Fail. 2000;6(3): 257-263.

14.

Crespo MJ , Altieri PI , Escobales N. Enhanced contractility of Ang II in the aorta of cardiomyopathic hamsters is mediated by an increased Ang II-binding capacity and release of ET-1. Vasc Pharmacol. 2006;44:247-252.

15.

Crespo MJ , Cruz N. , Altieri PI , Escobales N. Enalapril and losartan are more effective than carvedilol in preventing dilated cardiomyopathy in the Syrian cardiomyopathic hamster. J Cardiovasc Pharmacol Ther. 2008;13(3):199-206.

16.

Cruz N. , Arocho L. , Rosario L. , Crespo MJ Chronic administration of Carvedilol improves cardiac function of 6-month-old Syrian cardiomyopathic hamsters. Pharmacology. 2007;80(2-3): 144-150.

17.

Escobales N. , Crespo MJ. Angiotensin II-dependent vascular alterations in young cardiomyopathic hamsters: role for oxidative stress. Vascul Pharmacol. 2006;44(1):22-28.

18.

Fiordaliso F. , Bianchi R. , Staszewsky L. , et al. Antioxidant treatment attenuates hyperglycemia-induced cardiomyocyte death in rats. J Mol Cell Cardiol. 2004;37(5):959-968.

19.

Rauchová H. , Pechánová O. , Kunes J. , Vokurková M. , Dobesová Z. , Zicha J. Chronic N-acetylcysteine administration prevents development of hypertension in N(omega)-nitro-L-arginine methyl ester-treated rats: the role of reactive oxygen species. Hypertens Res. 2005;28(5):475-482.

20.

Matsuhisa S. , Otani H. , Okazaki T. , et al. N-acetylcysteine abolishes the protective effect of losartan against left ventricular remodeling in cardiomyopathy hamster . Antioxid Redox Signal. 2008;10(12):1999-2008.

21.

Ikeda Y. , Martone M. , Gu Y. , et al. Altered membrane proteins and permeability correlate with cardiac dysfunction in cardiomyopathic hamsters. Am J Physiol Heart Circ Physiol. 2000;278(4): H1362-H1370.

22.

Scharfstein JS , Keaney JF Jr , Slivka A. , et al. In vivo transfer of nitric oxide between a plasma protein-bound reservoir and low molecular weight thiols. J Clin Invest. 1994;94(4): 1432-1439.

23.

Pieper GM , Siebeneich W. Oral administration of the antioxidant, N-acetylcysteine, abrogates diabetes-induced endothelial dysfunction. J Cardiovasc Pharmacol. 1998;32(1):101-105.

24.

Prasad A. , Andrews NP , Padder FA , Husain M. , Quyyumi AA Glutathione reverses endothelial dysfunction and improves nitric oxide bioavailability . J Am Coll Cardiol. 1999;34(2):507-514.

25.

Adamy C. , Mulder P. , Khouzami L. , et al. Neutral sphingomyelinase inhibition participates to the benefits of N-acetylcysteine treatment in post-myocardial infarction failing heart rats. J Mol Cell Cardiol. 2007;43(3):344-353.

26.

Escobales N. , Crespo MJ Early pathophysiological alterations in experimental cardiomyopathy: the Syrian cardiomyopathic hamsters. P R Health Sci J. 2008;27(4):307-314.

27.

Boesgaard S. , Aldershvile J. , Poulsen HE , Christensen S. , Dige-Petersen H. , Giese J. N-acetylcysteine inhibits angiotensin converting enzyme in vivo. J Pharmacol Exp Ther. 1993 ;265(3): 1239-1244.